Our research group at Oslo University Hospital is dedicated to advancing the understanding of tankyrase 1 and tankyrase 2 (TNKS1/2), key enzymes in the PARP family that regulate protein function, interactions, and degradation through ADP-ribosylation and downstream signaling. TNKS1/2 play crucial roles in controlling WNT/β-catenin and Hippo signaling pathways, both of which are central to disease mechanisms such as cancer, immune evasion, and fibrosis.
Company Details
- Address
- Oslo, No
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- tankyrase inhibitor, wnt signaling, Hippo signaling, lung fibrosis, melanoma, YAP signaling, cancer therapy.
- HQ
- Oslo
- Competitors
- Scale Biosciences, CRESCO - Centre For Embryology and Healthy Development, Syneos Health, Parse Biosciences, Norwegian Centre for Molecular Biosciences and Medicine (NCMBM), University of Oslo, Immix Biopharma (Nasdaq: IMMX), Miltenyi Biotec, Odin Therapeutics, PL BioScience GmbH, Libertad Con Ciencia.
Cell Signaling And Drug Discovery Group (Waaler) Questions
Cell Signaling And Drug Discovery Group (Waaler)'s website is https://www.ous-research.no/waaler
Cell Signaling And Drug Discovery Group (Waaler)'s LinkedIn profile is https://no.linkedin.com/company/cellsignaling
Cell Signaling And Drug Discovery Group (Waaler)'s industry is
Biotechnology Research
Cell Signaling And Drug Discovery Group (Waaler)'s top competitors are
Scale Biosciences,
Cresco - Centre For Embryology And Healthy Development,
Syneos Health,
Parse Biosciences,
Norwegian Centre For Molecular Biosciences And Medicine (Ncmbm), University Of Oslo,
Immix Biopharma (Nasdaq: Immx),
Miltenyi Biotec,
Odin Therapeutics,
Pl Bioscience Gmbh,
Libertad Con Ciencia.
Cell Signaling And Drug Discovery Group (Waaler)'s categories are Biotechnology Research
